Journal of Alzheimer's disease : JAD · 2019
An Indoor Therapeutic Garden for Behavioral Symptoms in Alzheimer's Disease: A Randomized Controlled Trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pedrinolla Anna, Tamburin Stefano, Brasioli Anna, Sollima Alessio, Fonte Cristina, Muti Ettore, Smania Nicola, Schena Federico, Venturelli Massimo
Аннотация
BACKGROUND: Behavioral and psychological symptoms of dementia (BPSD) affect 60-90% of patients with Alzheimer's disease (AD).
OBJECTIVE: To determine if environmental therapy is an effective strategy to reduce BPSD, we tested 163 patients with AD with Neuropsychiatric Inventory (NPI) before and after 6 months of an indoor therapeutic garden (TG) or standard environment.
METHODS: A single-blind randomized controlled trial on AD patients with BPSD. Participants were randomized to an indoor TG (N = 82), or standard environment (control, N = 81) for 6 months.
PRIMARY OUTCOME: change in the NPI score from baseline (T0) to end of treatment (T1).
SECONDARY OUTCOMES: change in use of quetiapine, cognition, activities of daily living, salivary cortisol, blood pressure from T0 to T1.
RESULTS: NPI score significantly ameliorated (TG versus control: -31.8 points), quetiapine dosage (-150 mg), blood pressure (-2.6 mm Hg), and salivary cortisol (-6.4 to -2.1 Nmol/l) were significantly reduced, the Mini-Mental State Examination significantly improved (1.8 points) in the TG versus control arm at T1 (p < 0.001). No adverse events were reported.
CONCLUSION: The indoor TG seems safe and may reduce BPSD, medication intake, and cortisol levels in AD.
OBJECTIVE: To determine if environmental therapy is an effective strategy to reduce BPSD, we tested 163 patients with AD with Neuropsychiatric Inventory (NPI) before and after 6 months of an indoor therapeutic garden (TG) or standard environment.
METHODS: A single-blind randomized controlled trial on AD patients with BPSD. Participants were randomized to an indoor TG (N = 82), or standard environment (control, N = 81) for 6 months.
PRIMARY OUTCOME: change in the NPI score from baseline (T0) to end of treatment (T1).
SECONDARY OUTCOMES: change in use of quetiapine, cognition, activities of daily living, salivary cortisol, blood pressure from T0 to T1.
RESULTS: NPI score significantly ameliorated (TG versus control: -31.8 points), quetiapine dosage (-150 mg), blood pressure (-2.6 mm Hg), and salivary cortisol (-6.4 to -2.1 Nmol/l) were significantly reduced, the Mini-Mental State Examination significantly improved (1.8 points) in the TG versus control arm at T1 (p < 0.001). No adverse events were reported.
CONCLUSION: The indoor TG seems safe and may reduce BPSD, medication intake, and cortisol levels in AD.